Stock listing
LSE:0A8I Genprex, Inc. Share Price
UK listing (LSE) of Genprex, Inc. · home listing NASDAQ:GNPX
Follow Genprex, Inc. into a list and get an email when it puts out news.
Share price · LSE:0A8I
$1.49 USD -0.17 (-10.1%)
Close on Nov 20, 2026
- Day range
- $1.49 – $1.80 USDNov 20, 2026
- Volume
- 3,487 sharesNov 20, 2026
- 52-week range
- $1.49 – $80.52 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $6,392 USDMedian day 516 shares · 1 day with no trades · last 3 months, Aug 20, 2026 – Nov 6, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:GNPX · Home | $1.45 USD | -0.26 (-15.2%) | 93,404 | $1.64 | $1.67 | $1.45 | $1.71 | Close on Nov 20, 2026 |
| LSE:0A8I | $1.492 USD | -0.168 (-10.1%) | 3,487 | $1.64 | $1.80 | $1.492 | $1.66 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 6, 2026 · LSE:0A8I · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $2.118 | +0.008 | +0.4% | $2.06 | $2.20 | $1.96 | 423 | |
| $2.11 | -0.04 | -1.9% | $2.00 | $2.24 | $2.00 | 3,450 | |
| $2.15 | -0.14 | -6.1% | $2.55 | $2.71 | $2.14 | 9,839 | |
| $2.29 | -0.031 | -1.3% | $2.29 | $2.29 | $2.29 | 4 | |
| $2.321 | +0.061 | +2.7% | $2.32 | $2.36 | $2.25 | 437 | |
| $2.26 | +0.26 | +13.0% | $1.90 | $2.26 | $1.90 | 1,037 | |
| $2.00 | +0.04 | +2.0% | $1.94 | $2.03 | $1.94 | 143 | |
| $1.96 | +0.04 | +2.1% | $1.84 | $1.98 | $1.84 | 119 | |
| $1.92 | +0.13 | +7.3% | $1.89 | $1.92 | $1.75 | 123 | |
| $1.79 | -0.02 | -1.1% | $1.89 | $2.00 | $1.79 | 32 | |
| $1.81 | -0.23 | -11.3% | $2.05 | $2.13 | $1.81 | 251 | |
| $2.04 | +0.03 | +1.5% | $1.97 | $2.07 | $1.97 | 512 | |
| $2.01 | -0.15 | -6.9% | $2.07 | $2.31 | $1.96 | 2,440 | |
| $2.16 | +0.07 | +3.3% | $2.02 | $2.16 | $2.02 | 595 | |
| $2.09 | -0.11 | -5.0% | $2.16 | $2.29 | $2.09 | 261 | |
| $2.20 | -0.17 | -7.2% | $2.26 | $2.31 | $2.18 | 726 | |
| $2.37 | -0.03 | -1.2% | $2.30 | $2.42 | $2.16 | 250 | |
| $2.40 | -0.22 | -8.4% | $2.60 | $2.60 | $2.40 | 299 | |
| $2.62 | -0.054 | -2.0% | $2.69 | $2.69 | $2.50 | 669 | |
| $2.674 | -0.046 | -1.7% | $2.685 | $2.88 | $2.60 | 610 | |
| $2.72 | -0.08 | -2.9% | $3.01 | $3.07 | $2.63 | 2,560 | |
| $2.80 | +0.11 | +4.1% | $2.56 | $2.80 | $2.55 | 2,389 | |
| $2.69 | +0.02 | +0.7% | $2.60 | $2.77 | $2.60 | 519 | |
| $2.67 | -0.118 | -4.2% | $2.75 | $2.75 | $2.58 | 361 | |
| $2.788 | +0.128 | +4.8% | $2.63 | $2.80 | $2.62 | 3,235 | |
| $2.66 | -0.03 | -1.1% | $2.56 | $2.94 | $2.43 | 329 | |
| $2.69 | -0.17 | -5.9% | $3.10 | $3.10 | $2.59 | 597 | |
| $2.86 | +0.13 | +4.8% | $2.95 | $3.04 | $2.73 | 2,446 | |
| $2.73 | -0.15 | -5.2% | $2.93 | $2.93 | $2.73 | 799 | |
| $2.88 | -0.48 | -14.3% | $3.25 | $3.52 | $2.74 | 8,243 | |
| $3.36 | -0.04 | -1.2% | $3.32 | $3.55 | $3.30 | 811 | |
| $3.40 | -0.51 | -13.0% | $3.52 | $3.70 | $3.36 | 9,516 | |
| $3.91 | +0.335 | +9.4% | $3.93 | $4.20 | $3.48 | 40,374 | |
| $3.575 | -0.005 | -0.1% | $3.72 | $3.72 | $3.46 | 586 | |
| $3.58 | +0.13 | +3.8% | $3.31 | $3.65 | $3.31 | 542 | |
| $3.45 | +0.10 | +3.0% | $3.55 | $3.60 | $3.37 | 35 | |
| $3.35 | 0.00 | 0.0% | $3.40 | $3.46 | $3.341 | 2,643 | |
| $3.351 | +0.01 | +0.3% | $3.50 | $3.50 | $3.22 | 271 | |
| $3.34 | -0.11 | -3.2% | $3.38 | $3.47 | $3.34 | 650 | |
| $3.45 | +0.02 | +0.6% | $3.28 | $3.50 | $3.28 | 437 | |
| $3.43 | +0.05 | +1.5% | $3.48 | $3.48 | $3.20 | 295 | |
| $3.38 | -0.11 | -3.1% | $3.50 | $3.75 | $3.35 | 204 | |
| $3.49 | -0.11 | -3.1% | $3.40 | $3.62 | $3.40 | 67 | |
| $3.60 | +0.229 | +6.8% | $3.41 | $3.62 | $3.41 | 2,149 | |
| $3.37 | 0.00 | 0.0% | $3.37 | $3.37 | $3.37 | 0 | |
| $3.37 | -0.01 | -0.3% | $3.50 | $3.60 | $3.37 | 40 | |
| $3.38 | -0.15 | -4.2% | $3.59 | $3.59 | $3.38 | 39 | |
| $3.53 | +0.03 | +0.9% | $3.48 | $3.68 | $3.28 | 265 | |
| $3.50 | -0.16 | -4.4% | $3.64 | $3.77 | $3.50 | 125 | |
| $3.66 | -0.059 | -1.6% | $3.76 | $3.76 | $3.65 | 393 | |
| $3.72 | -0.259 | -6.5% | $4.04 | $4.14 | $3.72 | 605 | |
| $3.978 | -0.062 | -1.5% | $3.80 | $4.16 | $3.80 | 640 | |
| $4.04 | -0.02 | -0.5% | $4.03 | $4.17 | $3.951 | 3,910 | |
| $4.06 | -0.125 | -3.0% | $3.77 | $4.18 | $3.77 | 979 | |
| $4.185 | +0.235 | +5.9% | $3.89 | $4.30 | $3.75 | 98 | |
| $3.95 | -0.09 | -2.2% | $4.19 | $4.20 | $3.90 | 313 |
Splits
3 splits since 2024 · LSE:0A8I · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 1-for-22 | Consolidation | |
| 11-for-25 | Consolidation | |
| 2503-for-91 | Split |
- Ticker
- LSE:0A8I
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- LSE
- Currency
- USD
What changed lately
Latest news release · Nov 19, 2026
Genprex Presents Preclinical Data Identifying TROP2 as a Potential Predictive Biomarker for Reqorsa® Gene Therapy in Lung Cancer
Latest deck · Jul 14, 2026
Investor Presentation (July 2026)
Investor deck · 66 slides
Latest news
Genprex Presents Data Showing Reqorsa® Gene Therapy Activates Cellular Repair and Maintenance Programs Linked to Aging Biology in Patients, Supporting TUSC2 as a Key Regulator of Resilience to Aging-Associated Stress
Nov 5, 2026
Closed $2.11 (-1.9%) on Nov 5, 2026
Genprex Announces New Research Identifying TROP2 as a Potential Predictive Biomarker to Reqorsa® Gene Therapy in Lung Cancer
Nov 4, 2026
Closed $2.15 (-6.1%) on Nov 4, 2026
Genprex to Present TUSC2 Research from Sponsored Collaboration with Meharry Medical College at the Gerontological Society of America 2026 Annual Scientific Meeting
Oct 28, 2026
Closed $1.96 (+2.1%) on Oct 28, 2026
Genprex Highlights New Preclinical Data Identifying Role of TUSC2, the Gene Used in REQORSA®, in Maintaining Cellular Function During Brain Aging
Oct 21, 2026
Closed $2.01 (-6.9%) on Oct 21, 2026
Genprex to Present at the H.C. Wainwright 28th Annual Global Investment Conference
Sep 8, 2026
Closed $3.60 (+6.8%) on Sep 8, 2026
Andelyn Biosciences to Scale Manufacturing for Genprex's Diabetes Gene Therapy Program
Sep 1, 2026
Closed $3.50 (-4.4%) on Sep 1, 2026
Genprex Selects Leading Clinical and Commercial Contract Development and Manufacturing Organization for Manufacturing Scale Up of Diabetes Gene Therapy
Aug 18, 2026
Closed $4.10 (-8.9%) on Aug 18, 2026
Genprex Announces Collaboration with Roche Diagnostics for Biomarker Assay Validation Studies
Aug 3, 2026
Closed $5.05 (-14.4%) on Aug 3, 2026
Genprex, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 24 in the last 12 months · 130 in all · newest Nov 19, 2026 · oldest 2019
- Decks
- 28 decks · latest Jul 14, 2026
Where Genprex, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:GNPX · Home listing | NASDAQ | United States | USD |
| BOATS:GNPX | BOATS | United States | USD |
| Frankfurt:2DE | Frankfurt | Germany | EUR |
| LSE:0A8I · This page | LSE | United Kingdom | USD |
| gettex:2DE | gettex | Germany | EUR |
| Munich:2DE | Munich | Germany | EUR |
Valuation
Price/book 0.1× against a median of 0.5×: the lowest of 7 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- −$13.41M USD
- P/E
- Loss
- EV/sales
- No revenue
- EV/EBITDA
- No depreciation figure on 6ix yet
- Price/book
- 0.1×
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- 0.0×
- Beta vs S&P 500
- 1.08
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Genprex, Inc. · NASDAQ:GNPX | US$1.94M | −US$13.41M | n/a | n/a | n/a | 0.1× | n/a | 0.0× | 1.08 |
| Medicus Pharma Ltd. · NASDAQ:MDCX | US$2.18M | −US$2.73M | n/a | n/a | n/a | n/a | n/a | n/a | 2.03 |
| Senti Biosciences Holdings, Inc. · NASDAQ:SNTI | US$2.06M | −US$3.49M | n/a | −47.2× | n/a | n/a | n/a | n/a | 2.91 |
| CASI Pharmaceuticals, Inc. · OTC:CASIF | US$2.06M | US$38.79M | n/a | 1.9× | n/a | n/a | −218.6% | n/a | -0.07 |
| Vectus Biosystems Limited · ASX:VBS | US$2.02M | US$50,946 | 1.9× | n/a | n/a | 1.3× | n/a | 0.2× | n/a |
| Decoy Therapeutics Inc. · NASDAQ:DCOY | US$1.98M | −US$6.19M | n/a | −11.6× | n/a | 0.4× | n/a | 0.0× | 1.28 |
| Propanc Biopharma, Inc. · NASDAQ:PPCB | US$1.84M | US$1.62M | n/a | n/a | n/a | 0.3× | n/a | 0.0× | 1.39 |
| Argent Biopharma Ltd · ASX:RGT | US$1.79M | US$8.05M | n/a | 75.4× | n/a | n/a | n/a | n/a | n/a |
| Calidi Biotherapeutics, Inc. · AMEX:CLDI | US$1.76M | −US$2.19M | n/a | n/a | n/a | 1.1× | n/a | 0.0× | 1.86 |
| Kala Bio, Inc. · NASDAQ:KALA | US$1.74M | −US$5.49M | n/a | n/a | n/a | 0.2× | n/a | 0.0× | 2.76 |
| SOHM, Inc. · OTC:SHMN | US$1.74M | US$4.99M | n/a | 5.5× | n/a | 0.5× | −28.1% | 0.9× | -0.10 |
| Median of the others | US$1.91M | −US$1.07M | 1.9× | 1.9× | 0.5× | −123.3% | 0.0× | 1.63 |
Forecasts
Analysts' consensus from EODHD, read Nov 15, 2026. Not 6ix's view and not investment advice.
- Price target
- 7.50 USD · Analysts' mean
- EPS, year to Dec 2024
- -4.25 · 1 analyst
Team and board
Officers
| Officer | Role |
|---|---|
| Ryan M. Confer | President, Chief Executive Officer, Chief Financial Officer |
| Kate Combs | Vice President of Clinical Operations |
| Celina Laney | Chief of Staff |
| Greg Jancarik | Senior Director and Corporate Controller |
| Kalyn Dabbs | Director of Communications |
| Tracy Huynh | Accounting Manager |
Board
| Director | Role |
|---|---|
| Jose A. Moreno Toscano | Board Chairman |
| Brent Longnecker | Board Director |
| William Wilson | Board Director |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 13, 2026 | −14.0% |
| Q2 2026 | Aug 14, 2026 | −8.1% |
| Q1 2026 | Jun 3, 2026 | −5.4% |
| Q4 2025 | Mar 27, 2026 | −5.8% |
| Q3 2025 | Nov 14, 2025 | −2.4% |
| Q2 2025 | Aug 14, 2025 | −5.8% |
| Q1 2025 | Apr 1, 2025 · Before open | −6.1% |
| Q4 2024 | Mar 31, 2025 · After close | −6.1% |
| Q3 2024 | Nov 13, 2024 · Before open | −23.4% |
| Q2 2024 | Aug 9, 2024 · After close | −11.3% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 15, 2024 · After close | −3.4% |
| Q4 2023 | Feb 26, 2024 · After close | −4.8% |
| Q3 2023 | Nov 14, 2023 · After close | +10.6% |
| Q2 2023 | Aug 21, 2023 · After close | +8.0% |
| Q1 2023 | May 22, 2023 · After close | −0.3% |
| Q4 2022 | Mar 31, 2023 · After close | −3.3% |
| Q3 2022 | Nov 14, 2022 · Before open | +2.2% |
| Q2 2022 | Aug 12, 2022 · After close | +18.1% |
| Q1 2022 | May 13, 2022 · After close | −0.7% |
| Q4 2021 | Mar 30, 2022 · After close | −1.7% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (July 2026) | Investor deck | 66 slides | Jul 14, 2026 |
| Investor Presentation (April 2026) | Investor deck | 64 slides | Apr 21, 2026 |
| Investor Presentation (January 2026) | Investor deck | 64 slides | Jan 7, 2026 |
| Investor Presentation (October 2025) | Investor deck | 62 slides | Oct 17, 2025 |
| Investor Presentation (January 2025) | Investor deck | 61 slides | Jan 13, 2025 |
| Investor Presentation (June 2024) | Investor deck | 57 slides | June 2024 |
| Investor Presentation (February 2024) | Investor deck | 54 slides | February 2024 |
| Investor Presentation (January 2024) | Investor deck | 52 slides | Jan 5, 2024 |
| Investor Presentation (September 2023) | Investor deck | 52 slides | Sep 8, 2023 |
| Investor Presentation (January 2023) | Investor deck | 49 slides | Jan 6, 2023 |
All 28 decks
Financings
| Raise | Date |
|---|---|
| Registered direct offering of shares of common stock, with unregistered short-term warrants Announced: about US$3.4M · US$9 a share · Warrants at US$8.75 for 24 months · H.C. Wainwright & Co. Dealers: H.C. Wainwright & Co. (lead) Use of proceeds: Working capital and general corporate purposes | Oct 28, 2025 |
| Registered direct offering of shares of common stock, with unregistered short-term warrants Announced: about US$2.7M · US$11.21 a share · Warrants at US$11 for 24 months · H.C. Wainwright & Co. Dealers: H.C. Wainwright & Co. (lead) Use of proceeds: Working capital and general corporate purposes | Oct 23, 2025 |
Open Financings · Read by 6ix AI from the company's releases
IPO
Priced at US$5.00 a share on Oct 13, 2017.
- Price
- US$5.00 a share
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | Jun 5, 2017 |
| Filed publicly | Jul 21, 2017 |
| Amended 6 times | Newest Oct 10, 2017 |
| Shares registered with an exchange | Oct 13, 2017 |
| Declared effective by the SEC | Oct 13, 2017 |
| Final prospectus, with the price | Oct 13, 2017 |
Filings
| Filing | Filed |
|---|---|
| EFFECT · Notice that a registration is effective | Oct 13, 2017 |
| 424B4 · Prospectus | Oct 13, 2017 |
| 8-A12B · Registration of shares for listing on an exchange | Oct 13, 2017 |
| CORRESP · Letter to the SEC | Oct 12, 2017 |
| CORRESP · Letter to the SEC | Oct 12, 2017 |
| CORRESP · Letter to the SEC | Oct 10, 2017 |
| S-1/A · Registration statement, amended | Oct 10, 2017 |
| CORRESP · Letter to the SEC | Sep 26, 2017 |
| S-1/A · Registration statement, amended | Sep 26, 2017 |
| CORRESP · Letter to the SEC | Sep 22, 2017 |
All 26 filings
| Filing | Filed |
|---|---|
| S-1/A · Registration statement, amended | Sep 22, 2017 |
| UPLOAD · Letter from the SEC | Sep 19, 2017 |
| FWP · Free writing prospectus | Sep 15, 2017 |
| CORRESP · Letter to the SEC | Sep 15, 2017 |
| S-1/A · Registration statement, amended | Sep 15, 2017 |
| CORRESP · Letter to the SEC | Sep 8, 2017 |
| S-1/A · Registration statement, amended | Sep 8, 2017 |
| UPLOAD · Letter from the SEC | Sep 1, 2017 |
| CORRESP · Letter to the SEC | Aug 18, 2017 |
| S-1/A · Registration statement, amended | Aug 18, 2017 |
| UPLOAD · Letter from the SEC | Aug 4, 2017 |
| S-1 · Registration statement | Jul 21, 2017 |
| CORRESP · Letter to the SEC | Jul 20, 2017 |
| UPLOAD · Letter from the SEC | Jun 30, 2017 |
| DRSLTR · Letter to the SEC with a draft | Jun 5, 2017 |
| DRS · Draft registration statement | Jun 5, 2017 |
Open IPO · From the cover of the final prospectus (424B4) filed Oct 13, 2017
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of revenue | 6.69K | 15.0K | 25.6K | 22.5K | 22.8K | 13.1K | 0 | 0 | 0 | |
| Gross profit | -6.69K | -15.0K | -25.6K | -22.5K | -22.8K | -13.1K | 0 | 0 | 0 | |
| Research and development | 9.43M | 10.5M | 17.6M | 11.5M | 8.97M | 7.30M | 1.97M | 971.4K | 289.9K | 354.9K |
| Selling, general and administrative | 6.09M | 10.6B | 13.4M | 12.3M | 11.0M | 10.6M | 11.4M | 11.4M | 3.02M | 3.78M |
| Operating income | -15.5M | -21.2M | -31.1M | -23.8M | -20.7M | -18.0M | -10.7M | -12.4M | -3.31M | -4.13M |
| Depreciation and amortization | 0 | 6.69K | 15.0K | 25.6K | 22.5K | 22.8K | 13.1K | 5.88K | 3.24K | 862 |
| EBITDA | -15.5M | -21.2M | -31.0M | -23.8M | -20.6M | -17.9M | -10.7M | -12.4M | -3.31M | -4.13M |
| Interest expense | 739.9K | 0 | 18.1M | 5.13K | 0 | 38.0K | 38.0K | 1.89K | 0 | |
| Income before tax | -16.2M | -21.1M | -30.9M | -23.7M | -20.7M | -17.9M | -10.7M | -12.4M | -3.31M | -4.13M |
| Income tax | 0 | 2.65K | 0 | 0 | -5.13K | -18.8K | 29.2K | 29.2K | 80 | 0 |
| Net income | -16.2M | -21.1M | -30.9M | -23.7M | -20.7M | -17.9M | -10.7M | -12.4M | -3.31M | -4.13M |
| Earnings per share, basic | -17.40 | -266.89 | -22.56 | -19.80 | -0.44 | -0.51 | -0.66 | -0.90 | -0.29 | -0.38 |
| Earnings per share, diluted | -0.42 | -0.51 | -0.66 | -0.90 | -0.29 | -0.38 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 7.83M | 1.60M | 6.74M | 21.0M | 38.6M | 27.3M | 2.00M | 8.60M | 161.3K | 1.60M |
| Short-term investments | 1.60B | 0 | ||||||||
| Receivables | 0 | 34.9K | 0 | 127 | 655 | 9.30K | 8.84K | 8.18K | ||
| Inventory | 3.01M | 801.8K | 0 | |||||||
| Current assets | 8.36M | 2.08M | 7.53M | 21.5M | 39.1M | 27.7M | 2.98M | 8.85M | 193.6K | 1.64M |
| Property, plant and equipment | 0 | 0 | 7.86K | 23.0K | 48.6K | 39.4K | 44.7K | 24.4K | 7.80K | 5.16K |
| Goodwill | 0 | |||||||||
| Total assets | 10.2M | 4.12M | 10.7M | 25.1M | 42.9M | 31.4M | 3.53M | 9.27M | 1.26M | 1.91M |
| Accounts payable | 743.1K | 1.07M | 1.40M | 442.9K | 973.2K | 193.0K | 436.3K | 295.1K | 629.1K | 109.7K |
| Current liabilities | 2.17M | 2.50M | 3.25M | 2.81M | 1.59M | 450.7K | 510.7K | 387.8K | 831.0K | 285.7K |
| Long-term debt | 0 | |||||||||
| Total debt | 92.8K | 92.8K | 201.9K | |||||||
| Total liabilities | 2.20M | 2.50M | 3.25M | 2.81M | 1.59M | 450.7K | 510.7K | 387.8K | 831.0K | 285.7K |
| Shareholders' equity | 7.96M | 1.62M | 7.42M | 22.3M | 41.3M | 30.9M | 3.02M | 8.88M | 428.6K | 1.62M |
| Shares outstanding | 149.8K | 217.2K | 1.49M | 1.20M | 47.9M | 43.1M | 19.3M | 15.2M | 11.7M | 11.4M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -15.3M | -17.9M | -24.7M | -17.6M | -14.3M | -13.9M | -6.92M | -6.85M | -2.17M | -1.25M |
| Capital spending | -1 | 0 | -71.4K | 0 | -31.7K | -17.6K | -33.4K | -22.4K | -5.89K | -4.98K |
| Free cash flow | -15.3M | -17.1M | -24.8M | -17.6M | -14.3M | -14.0M | -6.95M | -6.87M | -2.18M | -1.25M |
| Cash from investing | 0 | 774.6K | -71.2K | -59.7K | -83.8K | -2.34M | -946.9K | -103.3K | -63.4K | -89.5K |
| Cash from financing | 21.5M | 12.0M | 10.6M | 6.43K | 25.7M | 41.6M | 1.27M | 15.4M | 794.0K | 2.71M |
| Dividends paid | -277.1M | 0 | ||||||||
| Share buybacks | 41.6M | 1.27M | 15.4M | 794.0K | 2.71M | |||||
| Change in cash | 6.23M | -5.14M | -14.2M | -17.7M | 11.3M | 25.3M | -6.60M | 8.44M | -1.44M | 1.37M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 10-Q · Quarterly report | Nov 13, 2026 | Quarterly report | SEC |
| 8-K · Current report | Nov 5, 2026 | Current report | SEC |
| 8-K · Current report | Nov 4, 2026 | Current report | SEC |
| 8-K · Current report | Oct 28, 2026 | Current report | SEC |
| 8-K · Current report | Oct 21, 2026 | Current report | SEC |
| 8-K · Current report | Aug 18, 2026 | Current report | SEC |
| 10-Q · Quarterly report | Aug 14, 2026 | Quarterly report | SEC |
| 8-K · Current report | Aug 5, 2026 | Current report | SEC |
| 8-K · Current report | Aug 3, 2026 | Current report | SEC |
| 8-K · Current report | Jul 30, 2026 | Current report | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 8-K · Current report | Jul 14, 2026 | Current report | SEC |
| S-8 · Registration statement for employee plans | Jun 26, 2026 | Offer document | SEC |
| 8-K · Current report | Jun 22, 2026 | Current report | SEC |
| 8-K · Current report | Jun 18, 2026 | Management or board change | SEC |
| 8-K · Current report | Jun 12, 2026 | Current report | SEC |
| S-3 · Registration statement | Jun 5, 2026 | Offer document | SEC |
| 8-K · Current report | May 26, 2026 | Current report | SEC |
| 8-K · Current report | May 14, 2026 | Current report | SEC |
| 10-Q · Quarterly report | May 13, 2026 | Quarterly report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 11, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Apr 30, 2026 | Current report | SEC |
| ARS · Annual report to shareholders | Apr 29, 2026 | Annual report | SEC |
| DEF 14A · Proxy statement | Apr 29, 2026 | Meeting notice | SEC |
| 8-K · Current report | Apr 28, 2026 | Current report | SEC |
| 8-K · Current report | Apr 21, 2026 | Current report | SEC |
| PRE 14A · Preliminary proxy statement | Apr 17, 2026 | Meeting notice | SEC |
| 4 · Change in ownership | Apr 15, 2026 | Insider trade | SEC |
| 10-K · Annual report | Mar 30, 2026 | Annual report | SEC |
| 8-K · Current report | Mar 18, 2026 | Current report | SEC |
| 4 · Change in ownership | Feb 27, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 27, 2026 | Insider trade | SEC |
| 8-K · Current report | Feb 23, 2026 | Current report | SEC |
| SCHEDULE 13G · Big-stake notice | Feb 11, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Feb 10, 2026 | Current report | SEC |
| 8-K · Current report | Jan 9, 2026 | Current report | SEC |
| S-8 · Registration statement for employee plans | Jan 9, 2026 | Offer document | SEC |
| 8-K · Current report | Jan 7, 2026 | Current report | SEC |
| 8-K · Current report | Jan 6, 2026 | Current report | SEC |
| 4 · Change in ownership | Dec 23, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 23, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 23, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 23, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 23, 2025 | Insider trade | SEC |
| 8-K · Current report | Dec 23, 2025 | Current report | SEC |
| EFFECT · Notice that a registration is effective | Dec 15, 2025 | Other filings | SEC |
| 424B3 · Prospectus | Dec 12, 2025 | Offer document | SEC |
| CORRESP · Letter to the SEC | Dec 10, 2025 | Other filings | SEC |
| S-1/A · Registration statement, amended | Nov 26, 2025 | Offer document | SEC |
| 8-K · Current report | Nov 26, 2025 | Current report | SEC |
| S-1 · Registration statement | Nov 21, 2025 | Offer document | SEC |
| 8-K · Current report | Nov 21, 2025 | Current report | SEC |
| 424B5 · Prospectus | Nov 21, 2025 | Offer document | SEC |
| 8-K · Current report | Nov 19, 2025 | Current report | SEC |
| 8-K · Current report | Nov 18, 2025 | Current report | SEC |
| S-8 · Registration statement for employee plans | Nov 14, 2025 | Offer document | SEC |
| 10-Q · Quarterly report | Nov 14, 2025 | Quarterly report | SEC |
| 424B5 · Prospectus | Nov 10, 2025 | Offer document | SEC |
| 8-K · Current report | Nov 4, 2025 | Current report | SEC |
| SCHEDULE 13G · Big-stake notice | Nov 3, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Oct 29, 2025 | Material contract | SEC |
| 424B5 · Prospectus | Oct 29, 2025 | Offer document | SEC |
| 8-K · Current report | Oct 28, 2025 | Current report | SEC |
| 8-K · Current report | Oct 24, 2025 | Material contract | SEC |
| 424B5 · Prospectus | Oct 24, 2025 | Offer document | SEC |
| 8-K · Current report | Oct 23, 2025 | Current report | SEC |
| 8-K · Current report | Oct 21, 2025 | Current report | SEC |
| 8-K · Current report | Oct 17, 2025 | Current report | SEC |
| EFFECT · Notice that a registration is effective | Sep 17, 2025 | Other filings | SEC |
| 424B3 · Prospectus | Sep 16, 2025 | Offer document | SEC |
| CORRESP · Letter to the SEC | Sep 12, 2025 | Other filings | SEC |
| S-1 · Registration statement | Sep 12, 2025 | Offer document | SEC |
| UPLOAD · Letter from the SEC | Sep 11, 2025 | Other filings | SEC |
| DRS · Draft registration statement | Sep 5, 2025 | Offer document | SEC |
| 8-K · Current report | Aug 20, 2025 | Current report | SEC |
| 8-K · Current report | Aug 18, 2025 | Current report | SEC |
| 8-K · Current report | Aug 15, 2025 | Management or board change | SEC |
| 10-Q · Quarterly report | Aug 14, 2025 | Quarterly report | SEC |
| RW · Request to withdraw a registration | Aug 5, 2025 | Other filings | SEC |
| DEFA14A · Additional proxy material | Aug 4, 2025 | Meeting notice | SEC |
| 8-K · Current report | Aug 4, 2025 | Current report | SEC |
| ARS · Annual report to shareholders | Jul 16, 2025 | Annual report | SEC |
| DEF 14A · Proxy statement | Jul 16, 2025 | Meeting notice | SEC |
| PRE 14A · Preliminary proxy statement | Jul 3, 2025 | Meeting notice | SEC |
| 4 · Change in ownership | Jul 1, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 1, 2025 | Insider trade | SEC |
| 8-K · Current report | Jun 24, 2025 | Current report | SEC |
| 8-K · Current report | Jun 23, 2025 | Current report | SEC |
| EFFECT · Notice that a registration is effective | Jun 18, 2025 | Other filings | SEC |
| 424B3 · Prospectus | Jun 17, 2025 | Offer document | SEC |
| CORRESP · Letter to the SEC | Jun 16, 2025 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Jun 16, 2025 | Other filings | SEC |
| S-1 · Registration statement | Jun 11, 2025 | Offer document | SEC |
| 8-K · Current report | Jun 11, 2025 | Material contract | SEC |
| 8-K · Current report | Jun 9, 2025 | Current report | SEC |
| S-1 · Registration statement | May 14, 2025 | Offer document | SEC |
| 10-Q · Quarterly report | May 12, 2025 | Quarterly report | SEC |
| 8-K · Current report | May 7, 2025 | Current report | SEC |
| 8-K · Current report | May 6, 2025 | Current report | SEC |
| 8-K · Current report | Apr 28, 2025 | Current report | SEC |
| DRS · Draft registration statement | Apr 24, 2025 | Offer document | SEC |
| NT 10-K · Late filing notice | Apr 1, 2025 | Explanation request | SEC |
| 10-K · Annual report | Mar 31, 2025 | Annual report | SEC |
| 4 · Change in ownership | Feb 19, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 19, 2025 | Insider trade | SEC |
| 8-K · Current report | Feb 18, 2025 | Material contract | SEC |
| 8-K · Current report | Feb 12, 2025 | Current report | SEC |
| S-8 · Registration statement for employee plans | Jan 24, 2025 | Offer document | SEC |
| 8-K · Current report | Jan 23, 2025 | Current report | SEC |
| SCHEDULE 13G · Big-stake notice | Jan 15, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Jan 13, 2025 | Current report | SEC |
| 424B5 · Prospectus | Dec 20, 2024 | Offer document | SEC |
| 8-K · Current report | Dec 16, 2024 | Current report | SEC |
| 4 · Change in ownership | Dec 6, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 6, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 6, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 6, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 6, 2024 | Insider trade | SEC |
| 8-K · Current report | Nov 20, 2024 | Current report | SEC |
| 8-K · Current report | Nov 19, 2024 | Current report | SEC |
| 10-Q · Quarterly report | Nov 13, 2024 | Quarterly report | SEC |
| 424B5 · Prospectus | Nov 8, 2024 | Offer document | SEC |
| 8-K · Current report | Nov 5, 2024 | Current report | SEC |
| SC 13G/A · Big-stake notice, amended | Oct 24, 2024 | Big-stake notice | SEC |
| 8-K · Current report | Oct 24, 2024 | Current report | SEC |
| SC 13G · Big-stake notice | Oct 22, 2024 | Big-stake notice | SEC |
| 8-K · Current report | Oct 15, 2024 | Current report | SEC |
| SC 13G · Big-stake notice | Oct 3, 2024 | Big-stake notice | SEC |
| 8-K · Current report | Sep 26, 2024 | Current report | SEC |
| 8-K · Current report | Sep 4, 2024 | Current report | SEC |
| 424B5 · Prospectus | Aug 16, 2024 | Offer document | SEC |
| 8-K · Current report | Aug 13, 2024 | Current report | SEC |
| 10-Q · Quarterly report | Aug 9, 2024 | Quarterly report | SEC |
| 8-K · Current report | Jun 27, 2024 | Current report | SEC |
| 8-K · Current report | Jun 24, 2024 | Management or board change | SEC |
| 424B5 · Prospectus | May 20, 2024 | Offer document | SEC |
| 10-Q · Quarterly report | May 15, 2024 | Quarterly report | SEC |
| 8-K · Current report | May 9, 2024 | Management or board change | SEC |
| ARS · Annual report to shareholders | Apr 29, 2024 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 29, 2024 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 29, 2024 | Meeting notice | SEC |
| S-8 · Registration statement for employee plans | Apr 17, 2024 | Offer document | SEC |
| 10-K · Annual report | Apr 1, 2024 | Annual report | SEC |
| 424B5 · Prospectus | Mar 20, 2024 | Offer document | SEC |
| 8-K · Current report | Mar 20, 2024 | Material contract | SEC |
| 8-K · Current report | Mar 6, 2024 | Current report | SEC |
| 8-K · Current report | Feb 26, 2024 | Current report | SEC |
| 4 · Change in ownership | Feb 21, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 21, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 21, 2024 | Insider trade | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 14, 2024 | Big-stake notice | SEC |
| 8-K · Current report | Feb 5, 2024 | Management or board change | SEC |
| 8-K · Current report | Feb 2, 2024 | Management or board change | SEC |
| 8-K · Current report | Jan 31, 2024 | Current report | SEC |
| 8-K · Current report | Jan 5, 2024 | Current report | SEC |
| 8-K · Current report | Dec 18, 2023 | Meeting outcome | SEC |
| 424B5 · Prospectus | Dec 13, 2023 | Offer document | SEC |
| 8-K · Current report | Dec 13, 2023 | Material contract | SEC |
| 10-Q · Quarterly report | Nov 14, 2023 | Quarterly report | SEC |
| DEFA14A · Additional proxy material | Nov 3, 2023 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Nov 3, 2023 | Meeting notice | SEC |
| PRE 14A · Preliminary proxy statement | Oct 23, 2023 | Meeting notice | SEC |
| 8-K · Current report | Oct 23, 2023 | Current report | SEC |
| 8-K · Current report | Sep 25, 2023 | Current report | SEC |
| 8-K · Current report | Sep 8, 2023 | Current report | SEC |
| 8-K · Current report | Sep 1, 2023 | Current report | SEC |
| 8-K/A · Current report, amended | Aug 21, 2023 | Current report | SEC |
| 10-Q · Quarterly report | Aug 21, 2023 | Quarterly report | SEC |
| NT 10-Q · Late filing notice | Aug 15, 2023 | Explanation request | SEC |
| SC 13G · Big-stake notice | Jul 24, 2023 | Big-stake notice | SEC |
| 424B5 · Prospectus | Jul 20, 2023 | Offer document | SEC |
| 8-K · Current report | Jul 19, 2023 | Material contract | SEC |
| 8-K · Current report | Jul 18, 2023 | Material contract | SEC |
| 8-K · Current report | Jul 14, 2023 | Current report | SEC |
| 4 · Change in ownership | Jun 29, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jun 29, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jun 29, 2023 | Insider trade | SEC |
| 8-K · Current report | Jun 27, 2023 | Meeting outcome | SEC |
| EFFECT · Notice that a registration is effective | Jun 12, 2023 | Other filings | SEC |
| CORRESP · Letter to the SEC | Jun 7, 2023 | Other filings | SEC |
| 8-K · Current report | May 26, 2023 | Current report | SEC |
| 10-Q · Quarterly report | May 22, 2023 | Quarterly report | SEC |
| NT 10-Q · Late filing notice | May 16, 2023 | Explanation request | SEC |
| 8-K/A · Current report, amended | May 12, 2023 | Current report | SEC |
| ARS · Annual report to shareholders | Apr 28, 2023 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 28, 2023 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 28, 2023 | Meeting notice | SEC |
| UPLOAD · Letter from the SEC | Apr 27, 2023 | Other filings | SEC |
| 8-K/A · Current report, amended | Apr 27, 2023 | Current report | SEC |
| 4 · Change in ownership | Apr 24, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Apr 24, 2023 | Insider trade | SEC |
| S-3 · Registration statement | Apr 21, 2023 | Offer document | SEC |
| 10-K · Annual report | Mar 31, 2023 | Annual report | SEC |
| 8-K · Current report | Mar 13, 2023 | Current report | SEC |
| 8-K · Current report | Mar 6, 2023 | Current report | SEC |
| 424B5 · Prospectus | Feb 28, 2023 | Offer document | SEC |
| 8-K · Current report | Feb 27, 2023 | Material contract | SEC |
| 4 · Change in ownership | Feb 22, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Feb 22, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Feb 22, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Feb 22, 2023 | Insider trade | SEC |
This page holds 200 of 492 filings. Open Filings
Cap table
Built by 6ix from Genprex, Inc.’s releases · as of Nov 9, 2026
- Common shares
- 1,334,753
- Fully diluted
- 1,334,753
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 1,334,753 | Nov 9, 2026 |
Share count over time
| Count | Shares |
|---|---|
| Nov 9, 2026 | 1,334,753 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| John N Bonfiglio Other companies: Qrons Inc (Chief Operating Officer · Jul 1, 2019 – Jul 1, 2019 · Past); Marker Therapeutics, Inc. (President and COO, Director · Jul 23, 2015 – Mar 9, 2017 · Past); Oragenics Inc. (President and CEO, Director · May 25, 2011 – Aug 13, 2014 · Past); Harrow, Inc. (President and CEO, Director · Oct 20, 2010 – Oct 20, 2010 · Past) | Director · Feb 12, 2019 – Feb 12, 2019 · Past |
| Catherine M Vaczy Other companies: Lisata Therapeutics, Inc. (General Counsel · Oct 31, 2008 – Apr 13, 2015 · Past) | EVP GC Chief Strategy Officer · Mar 12, 2020 – Apr 21, 2023 · Past |
| Mark Stanley Berger Other companies: Actinium Pharmaceuticals, Inc. (Delaware) (Chief Medical Officer · Mar 16, 2017 – Sep 1, 2021 · Past) | Chief Medical Officer · Since at least Sep 27, 2021 |
| Brent Longnecker | Director · Since at least Apr 14, 2026 |
| Celina Laney | Chief of Staff · Since at least Nov 5, 2026 |
| Greg Jancarik | Senior Director and Corporate Controller · Since at least Nov 4, 2026 |
| Hermant Kumar | Chief Mfgr & Tech Officer · Sep 27, 2021 – Feb 18, 2023 · Past |
| John Rodney Varner | Chairman, President and CEO, Director · Mar 28, 2018 – Feb 18, 2024 · Past |
| Jose A. Moreno Toscano | Board Chairman · Since at least Nov 5, 2026 |
| Kalyn Dabbs | Director of Communications · Since at least Oct 28, 2026 |
All 15 people
| Person | Seat |
|---|---|
| Kate Combs | Vice President of Clinical Operations · Since at least Nov 4, 2026 |
| Robert W Pearson | Director · Mar 28, 2018 – Dec 30, 2019 · Past |
| Ryan M. Confer | President, Chief Executive Officer, Chief Financial Officer · Since at least Jul 28, 2022 |
| Tracy Huynh | Accounting Manager · Since at least Nov 5, 2026 |
| William Wilson | Board Director · Since at least Nov 5, 2026 |
Log in to ask 6ix AI your own questions about Genprex, Inc.